Göm menyn

Publications for Gunnar Juliusson

Co-author map based on Web of Sciences articles 2007-

Publications mentioned in social media 3 times*

Journal Articles

Stephen P. Mulligan, Karin -Karlsson, Mats Stromberg, Viggo Jonsson, Devinder Gill, Jens Hammerstrom, Mark Hertzberg, Roger McLennan, Bertil Uggla, John Norman, Jonas Wallvik, Gunnel Sundstrom, Hemming Johansson, Yvonne Brandberg, Jan Liliemark and Gunnar Juliusson
  Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic
  Leukemia and Lymphoma, 2014, 55(12), 2769-2777.
 Web of Science® Times Cited: 5

H E Johnsen, C Geisler, E Juvonen, K Remes, Gunnar Juliusson, P Hornsten, S Kvaloy, G Kvalheim, G W Jurgensen, L M Pedersen, O J Bergmann, A Schmitz and M Boegsted
  Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment
  BONE MARROW TRANSPLANTATION, 2011, 46(1), 44-51.
 Web of Science® Times Cited: 2

Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Annette Vangsted, Anne Mylin, Christian Gluud, Gunnar Juliusson, Henrik Gregersen, Henrik Hjorth-Hansen, Ingerid Nesthus, Inger Marie S Dahl, Jan Westin, Johan Lanng Nielsen, Lene Meldgaard Knudsen, Lucia Ahlberg, Martin Hjorth, Niels Abildgaard, Niels Frost Andersen, Olle Linder and Finn Wisloeff
  Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
  LANCET ONCOLOGY, 2010, 11(10), 973-982.
 Web of Science® Times Cited: 54

John Carstensen, R Billström, A Gruber, E Hellström-Lindberg, M Höglund, Karin Karlsson, D Stockelberg, A Wahlin, M Åström, C Arnesson, U Brunell-Abrahamsson, E Fredriksson, E Holmberg, F Wiklund, Gunnar Juliusson and Kerstin Nordenskjöld
  Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival
  Leukemia, 2006, 20(1), 42-47.
 Web of Science® Times Cited: 46

S. Lenhoff, M. Hjorth, J. Westin, L. Brinch, B. Backstrom, K. Carlson, I. Christiansen, I.M. Dahl, P. Gimsing, J. Hammerstrom, H.E. Johnsen, Gunnar Juliusson, O. Linder, U.-H. Mellqvist, I. Nesthus, J.L. Nielsen, J.M. Tangen and I. Turesson
  Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group
  British Journal of Haematology, 2006, 133(4), 389-396.
 Web of Science® Times Cited: 46

Gunnar Juliusson, Niklas Theorin, Karin Karlsson, U Frödin and Claes Malm
  Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: Influence of Campath dose on lymphoid recovery, mixed chimerism and survival
  Bone Marrow Transplantation, 2006, 37(5), 503-510.
 Web of Science® Times Cited: 41

Kourosh Lotfi, Karin Karlsson, Anna Fyrberg, Gunnar Juliusson, Viggo Jonsson, Curt Peterson, Staffan Eriksson and Freidoun Albertioni
  The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia
  Biochemical Pharmacology, 2006, 71(6), 882-890.
 Web of Science® Times Cited: 22

Anders Castor, Lars Nilsson, Ingbritt Åstrand-Grundström, Miranda Buitenhuis, Carole Ramirez, Kristina Anderson, Bodil Strömbeck, Stanislaw Garwicz, Albert N Békássy, Kjeld Schmiegelow, Birgitte Lausen, Peter Hokland, Sören Lehmann, Gunnar Juliusson, Bertil Johansson and Sten Eirik W Jacobsen
  Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia
  Nature Medicine, 2005, 11(6), 630-637.

Kourosh Lotfi, Curt Peterson and Gunnar Juliusson
  Letter: Monitoring oral cyclosporine therapy
  Bone Marrow Transplantation, 2005, 36, 367-367.
 Web of Science® Times Cited: 2

C Crawley, M Lalancette, R Szydlo, M Gilleece, K Peggs, S Mackinnon, Gunnar Juliusson, Lucia Ahlberg, A Nagler, A Shimoni, A Sureda, JM Boiron, H Einsele, R Chopra, A Carella, J Cavenagh, A Gratwohl, F Garban, A Zander and B Bjorkstrand
  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
  Blood, 2005, 105(11), 4532-4539.
 Web of Science® Times Cited: 167

C Crawley, R Szydlo, M Lalancette, A Bacigalupo, A Lange, M Brune, Gunnar Juliusson, A Nagler, A Gratwohl, J Passweg, M Komarnicki, A Vitek, J Mayer, A Zander, J Sierra, A Rimbaldi, O Ringden, D Niederwieser and JF Apperley
  Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognóstic factors from the Chronic Leukemia Working Party of the EBMT
  Blood, 2005, 106(9), 2969-2976.

Anne-Tove Brenne, Lene Hejna Romstad, Peter Gimsing, Gunnar Juliusson, Ingemar Turesson, Pål Romundstad, Magne Borset, Anders Sundan and Anders Waage
  A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma
  Haematologica, 2004, 89(5), 552-556.
 Web of Science® Times Cited: 4

S Lindemalm, J Liliemark, Gunnar Juliusson, R Larsson and F Albertioni
  Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia
  Cancer Letters, 2004, 210(2), 171-177.
 Web of Science® Times Cited: 25

Anders Waage, Peter Gimsing, Gunnar Juliusson, Ingemar Turesson, Nina Gulbrandsen, Tommy Eriksson, Martin Hjorth, Johan Lanng Nielsen, Stig Lenhoff, Jan Westin and Finn Wislöff
  Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
  British Journal of Haematology, 2004, 125(2), 149-155.
 Web of Science® Times Cited: 26

Clelia T Storlazzi, Thoas Fioretos, Kajsa Paulsson, Bodil Strömbeck, Carin Lassen, Tomas Ahlgren, Gunnar Juliusson, Felix Mitelman, Mariano Rocchi and Bertil Johansson
  Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies
  Human Molecular Genetics, 2004, 13(14), 1479-1485.
 Web of Science® Times Cited: 43

Gerard Tobin, Ulf Thunberg, Karin Karlsson, Fiona Murray, Anna Laurell, Kerstin Willander, Gunilla Enblad, Mats Merup, Juhani Vilpo, Gunnar Juliusson, Christer Sundström, Ola Söderberg, Göran Roos and Richard Rosenquist
  Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia
  Blood, 2004, 104, 2879-2885.
 Web of Science® Times Cited: 180

A Gruber, M Björkholm, L Brinch, S Evensen, B Gustavsson, M Hedenus, Gunnar Juliusson, E Lofvenberg, I Nesthus, B Simonsson, M Sjö, L Stenke, JM Tangen, U Tidefelt, AM Uden, C Paul and J Liliemark
  A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
  Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, 2003, 27(4), 323-328.
 Web of Science® Times Cited: 27

Gunnar Juliusson, Karin Karlsson, Claes Malm, U Frödin, AS Mollen, G Backström and Peter Söderkvist
  Adjusted conditioning for allogeneic transplantation in a single center setting: Mixed chimerism heralds relapse
  Leukemia and Lymphoma, 2003, 44(4), 669-679.
 Web of Science® Times Cited: 5

G Tobin, U Thunberg, A Johnson, I Eriksson, O Soderberg, Karin Karlsson, M Merup, Gunnar Juliusson, J Vilpo, G Enblad, C Sundstrom, G Roos and R Rosenquist
  Chronic lymphocytic leukemias utilizing the V(H)3-21 gene display highly restricted V(lambda)2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope
  Blood, 2003, 101(12), 4952-4957.
 Web of Science® Times Cited: 214

Gunnar Juliusson, Martin Höglund, Karin Karlsson, Christina Löfgren, Lars Möllgård, Christer Paul, Ulf Tidefelt and Magnus Björkholm
  Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study
  British Journal of Haematology, 2003, 123(5), 810-818.
 Web of Science® Times Cited: 34

Kourosh Lotfi, Gunnar Juliusson and Freidoun Albertioni
  Pharmacological basis for cladribine resistance
  Leukemia and Lymphoma, 2003, 44(10), 1705-1712.
 Web of Science® Times Cited: 19

J Lundin, H Hagberg, R Repp, E Cavallin-Stahl, S Freden, Gunnar Juliusson, E Rosenblad, G Tjonnfjord, T Wiklund and A Osterborg
  Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
  Blood, 2003, 101(11), 4267-4272.
 Web of Science® Times Cited: 234

Johan D Söderholm, Claes Malm, Gunnar Juliusson and Rune Sjödahl
  Long-term endoscopic remission of Crohn disease after autologous stem cell transplantation for acute myeloid leukaemia
  Scandinavian Journal of Gastroenterology, 2002, 37(5), 613-616.
 Web of Science® Times Cited: 27

Gunnar Juliusson, Karin Karlsson and Claes Malm
  More potent graft-versus-myeloma effect than graft-versus-renal cell cancer effect
  Leukemia and Lymphoma, 2002, 43(11), 2233-2234.
 Web of Science® Times Cited: 1

Karin Karlsson, Mats Strömberg, Jan Liliemark, André Delannoy, S A N Johnson, Anja Porwit, Eva Kimby, Gerd Lärfars, Ilse Cristiansen, Göran Nilsson, Fredrik Celsing, Gunnel Sundström, Mikaela Luthman, Ulf Tidefelt, Jonas Wallvik and Gunnar Juliusson
  Oral cladribine for B-cell chronic lymphocytic leukaemia: Report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients
  British Journal of Haematology, 2002, 116(3), 538-548.
 Web of Science® Times Cited: 14

Ioannis Panagopoulos, Thoas Fioretos, Margareth Isaksson, Felix Mitelman, Bertil Johansson, Niklas Theorin and Gunnar Juliusson
  RT-PCR analysis of acute myeloid leukemia with t(8,16)(p11,p13): Identification of a novel MOZ/CBP transcript and absence of CBP/MOZ expression [1]
  Genes, Chromosomes and Cancer, 2002, 35(4), 372-374.
 Web of Science® Times Cited: 14

Gunnar Juliusson, Fredrik Celsing, Ingemar Turesson, Stig Lenhoff, Magnus Adriansson and Claes Malm
  Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
  British Journal of Haematology, 2000, 109(1), 89-96.
 Web of Science® Times Cited: 193

U Tidefelt, J Liliemark, A Gruber, B Sundman-Engberg, Gunnar Juliusson, L Stenke, A Elmhorn-Rosenborg, L Möllgård, S Lehman, D Xu, A Covelli, B Gustavsson, C Paul and E Liliemark
  P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of Deunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
  Journal of Clinical Oncology, 2000, 18, 1837-1844.
 Web of Science® Times Cited: 47

Chapters in Books

Gunnar Juliusson
  Common cytogenetic abnormalities
  Chronic lymphocytic leukemia. Molecular genetics, biology, diagnosis, and management, Humana Press Inc., 2004, 163-171.

Conference Articles

DJ De Angelo, C Schiffer, R Stone, P Amrein, H Fernandez, K Bradstock, M Tallman, J Foran, Gunnar Juliusson, D Liu, C Paul, D Russo, L Stenke, L Leopold, D Stevenson, M Richie and M Berger
  Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin to patients < 60 years old with untreated acute myeloid leukemia.
  Blood, 2002.

 Web of Science® Times Cited: 14

A Waage, L Romstad, AT Brenne, P Gimsing, Gunnar Juliusson, I Turesson, M Borset and A Sundan
  Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma.
  Blood, 2002.

 Web of Science® Times Cited: 2

CR Crawley, M Lalancette, R Szydlo, A Bacigalupo, A Lange, Gunnar Juliusson, O Ringden, A Gratwohl, J Mayer, J Hansz, AR Zander, A Vitek, ML Brune, A Urbano-Ispizua, D Niederwieser, G Mufti and JF Apperley
  Reduced intensity conditioned allografts for chronic myeloid leukaemia: A study from the chronic leukaemia working party of the EBMT.
  Blood, 2002.

C Crawley, M Lalanacette, R Szydlo, M Gilleece, Gunnar Juliusson, M Michallet, S Mackinnon, H Einsele, J Reiffers, AR Zander, E Carreras, A Carella, A Gratwohl, JJ Sotto, JD Cavenagh, D Niederweiser, F Ciceri and JF Apperley
  Reduced intensity conditioned allografts for myeloma: A study from the Chronic Leukaemia Working Party of the EBMT.
  Blood, 2002.

Gunnar Juliusson, K Karlsson, U Frodin, G Backstrom and Claes Malm
  Subcutaneous Campath1H instead of thymoglobulin in nonmyeloablative allogeneic transplantation: Reduced acute toxicity, but delayed lymphocyte recovery leading to more mixed chimerism, more fatal infections and impaired long-term survival
  Blood, 2002.

 Web of Science® Times Cited: 1

G Tobin, U Thunberg, A Johnson, I Eriksson, O Soderberg, K Karlsson, M Merup, G Enblad, Gunnar Juliusson, J Vilpo, C Sundstrom, G Roos and R Rosenquist
  V(a)3-21 gene utilizing chronic lymphocytic leukemias display restricted V lambda 2-14 gene usage and homologous CDR3s.
  Blood, 2002.

Gunnar Juliusson, CR Lofgren, L Mollgard, C Paul, M Hoglund, U Tidefelt and M Bjorkholm
  No additional toxicity from cladribine (CdA) when given with cytosin arabinoside and idarubicin (CCI) as primary treatment of acute myeloid leukemia in elderly patients: Results from a randomized phase II-study from the leukemia group of middle Sweden (LGMS).
  Blood, 2001.

 Web of Science® Times Cited: 7

Henrik Gréen, Malin Lindqvist Appell, Anna Lena Zackrisson, Gunnar Juliusson and Curt Peterson
  P-gp and mdr-1 mRNA in leukemic cells fromAML patients during chemotheraphy.
  Proceedings of the American Association for Cancer Research,2001, 2001.

M Lalancette, K Rezvani, R Szydlo, S Mackinnon, Gunnar Juliusson, M Michallet, S Slavin, F Frassoni, D Niederwieser, G Gahrton and J Apperley
  Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience.
  Blood, 2000.

 Web of Science® Times Cited: 7

Johan D Söderholm, Gunnar Juliusson and Rune Sjödahl
  Long-term endoscopic remission in a case of Crohn's disease after autologous bone marrow transplantation.
  Gastroenterology, 2000.

E Liliemark, Y Wang, U Tidefelt, C Paul, A Gruber, Gunnar Juliusson, Lilian Stenke, M Frostvik-Stolt, R Zhou, B Sundman-Engberg, B Gustavsson, C Pfister and J Liliemark
  Etoposide accumulation of AML cells is affected by PSC 833 in vivo and in vitro.
  Blood, 1999.

Gunnar Juliusson, F Celsing, I Turesson, M Adriansson and C Malm
  Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant.
  Blood, 1999.

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.


Responsible for this page: Peter Berkesand
Last updated: 2017-02-21